Загрузка...
Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine
Even though the rate of new human immunodeficiency virus type 1 (HIV-1) infections is gradually decreasing worldwide, an effective preventive vaccine for HIV-1 is still urgently needed. The recombinant Mycobacterium bovis BCG (rBCG) is promising for the development of an HIV-1 vaccine. Recently, we...
Сохранить в:
| Опубликовано в: : | Front Immunol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5880907/ https://ncbi.nlm.nih.gov/pubmed/29636755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.00643 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|